TW202134259A - 用肌凝蛋白調節劑之治療方法 - Google Patents

用肌凝蛋白調節劑之治療方法 Download PDF

Info

Publication number
TW202134259A
TW202134259A TW109139230A TW109139230A TW202134259A TW 202134259 A TW202134259 A TW 202134259A TW 109139230 A TW109139230 A TW 109139230A TW 109139230 A TW109139230 A TW 109139230A TW 202134259 A TW202134259 A TW 202134259A
Authority
TW
Taiwan
Prior art keywords
subject
dose
probnp
level
mavacetai
Prior art date
Application number
TW109139230A
Other languages
English (en)
Chinese (zh)
Inventor
艾咪 賽納特
里歐 卡羅斯 Ｌ 迪歐
湯姆士 卡爾森
馬修 愛德華茲 密萊夫
傑 Ｍ 愛德柏格
羅伯 麥克道爾
嬿斐 馬
莎拉 費納德斯
馬可 Ｊ 賽米葛恩
馬克思 派崔克 亨茲
凱西 Ｌ 藍柏
中偉 張
密林德 Ｙ 迪賽
史提夫 Ｅ 尼森
李宛瑛
亮 方
喬瑟夫 藍賓
丹尼爾 Ｌ 奧貝爾
布萊恩 艾德木德 康恩
路易斯 查爾斯 賽歐
Original Assignee
美商邁奧卡迪亞公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商邁奧卡迪亞公司 filed Critical 美商邁奧卡迪亞公司
Publication of TW202134259A publication Critical patent/TW202134259A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW109139230A 2019-11-10 2020-11-10 用肌凝蛋白調節劑之治療方法 TW202134259A (zh)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201962933517P 2019-11-10 2019-11-10
US62/933,517 2019-11-10
US201962933970P 2019-11-11 2019-11-11
US62/933,970 2019-11-11
US201962935922P 2019-11-15 2019-11-15
US62/935,922 2019-11-15
US202063001473P 2020-03-29 2020-03-29
US63/001,473 2020-03-29
US202063002302P 2020-03-30 2020-03-30
US63/002,302 2020-03-30
US202063006701P 2020-04-07 2020-04-07
US63/006,701 2020-04-07
US202063022573P 2020-05-10 2020-05-10
US63/022,573 2020-05-10
US202063059143P 2020-07-30 2020-07-30
US63/059,143 2020-07-30
US202063064450P 2020-08-12 2020-08-12
US63/064,450 2020-08-12

Publications (1)

Publication Number Publication Date
TW202134259A true TW202134259A (zh) 2021-09-16

Family

ID=75849342

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109139230A TW202134259A (zh) 2019-11-10 2020-11-10 用肌凝蛋白調節劑之治療方法

Country Status (13)

Country Link
US (2) US20230158027A1 (enExample)
EP (1) EP4054588A4 (enExample)
JP (2) JP7830321B2 (enExample)
KR (1) KR20220113387A (enExample)
CN (1) CN114945372A (enExample)
AU (1) AU2020378197A1 (enExample)
BR (1) BR112022008641A2 (enExample)
CA (1) CA3157629A1 (enExample)
CL (2) CL2022001217A1 (enExample)
IL (2) IL292840B1 (enExample)
MX (1) MX2022005465A (enExample)
TW (1) TW202134259A (enExample)
WO (1) WO2021092598A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL294501A (en) * 2020-01-28 2022-09-01 Teva Pharmaceuticals Int Gmbh Crystalline forms of Mawakamatan and procedures for obtaining them
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
TWI905319B (zh) * 2020-11-25 2025-11-21 大陸商深圳信立泰藥業股份有限公司 Ａｒｂ代謝產物與ｎｅｐ抑制劑的複合物在製備用於預防和/或治療腎病的藥物中的用途
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) * 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
EP4370116B1 (en) * 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
WO2023133163A1 (en) * 2022-01-05 2023-07-13 Prolaio, Inc. System and method for monitoring an efficacy of a treatment for a cardiac condition
EP4508035A1 (en) 2022-04-13 2025-02-19 Assia Chemical Industries Ltd. Solid state forms of mavacamten and process for preparation thereof
CN119789856A (zh) * 2022-04-26 2025-04-08 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法
JP2024009734A (ja) * 2022-07-11 2024-01-23 国立大学法人福井大学 血圧輸液制御補助プログラム、血圧輸液制御補助装置、血圧輸液制御補助システム及び課金方法
US20240091203A1 (en) * 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
CA3268270A1 (en) 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス， インコーポレイテッド キナゾリンジオン化合物およびその使用
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
IT202300016653A1 (it) 2023-08-03 2025-02-03 Olon Spa Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration
CN122070481A (zh) * 2023-11-01 2026-05-19 百时美施贵宝公司 基于蛋白质水平用肌球蛋白抑制剂进行治疗的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
EP3399907A4 (en) * 2016-01-04 2019-08-28 Aventusoft, LLC SYSTEM AND METHOD FOR MEASURING HEMODYNAMIC PARAMETERS FROM THE HEADLAPPING SIGNALS
IL322175A (en) * 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds

Also Published As

Publication number Publication date
KR20220113387A (ko) 2022-08-12
MX2022005465A (es) 2022-08-08
CL2022001217A1 (es) 2023-01-13
US20230158027A1 (en) 2023-05-25
JP2023501453A (ja) 2023-01-18
CL2026001520A1 (es) 2026-06-19
CA3157629A1 (en) 2021-05-14
CN114945372A (zh) 2022-08-26
EP4054588A1 (en) 2022-09-14
IL292840B1 (en) 2026-07-01
AU2020378197A1 (en) 2022-05-26
JP7830321B2 (ja) 2026-03-16
US20260207600A1 (en) 2026-07-23
JP2026094345A (ja) 2026-06-09
EP4054588A4 (en) 2023-12-13
BR112022008641A2 (pt) 2022-09-13
WO2021092598A1 (en) 2021-05-14
IL292840A (en) 2022-07-01
IL328632A (en) 2026-07-01

Similar Documents

Publication Publication Date Title
JP7830321B2 (ja) ミオシンモジュレーターによる治療方法
US12616697B2 (en) Methods of treatment with myosin modulator
US20250241903A1 (en) Treatment of systolic dysfunction
JP7832128B2 (ja) 心房機能不全の治療
JP2020529996A (ja) 肥大型心筋症の治療で使用するためのマバカムテン
TW202030189A (zh) 經四氫哌喃(thp)取代之雙環嘧啶二酮化合物
JP2025515491A (ja) ミオシン阻害剤の投与方法
AU775591B2 (en) Anxiety method
HK40077232A (en) Methods of treatment with myosin modulator
EA052373B1 (ru) Способы лечения модулятором миозина
US20250325531A1 (en) Treatment of systolic dysfunction
HK40091633A (en) Treatment of atrial dysfunction
EA046692B1 (ru) Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
TW201330848A (zh) 治療黑種病人高血壓之方法